October 1, 2011 (Vol. 31, No. 17)

We Work with Passion to Transform Life Science into New Possibilities for Our Customers

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare, and life science industries. Our products and services span our customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. At Lonza, we have strong capabilities in large and small molecules, cell therapy, endotoxin detection, peptides, amino acids, and niche bioproducts that play an important role in the development of novel medicines and healthcare products. Over a century ago, Lonza began as a small Swiss electricity company, producing chemicals on the banks of the river Lonza in the Valais region of the Swiss Alps. Today, we are a leader in chemical and biotech ingredients for the nutrition, hygiene, preservation, agro, and personal care markets.

Markets Served

Lonza continues to be the partner of choice for customers looking for an edge in the pharmaceutical and biotech market. By focusing on the seven markets we serve, BioResearch, Pharma&Biotech, Nutrition, MicrobialControl, Agriculture, MaterialsScience, and PersonalCare, we are able to better reflect all that Lonza does today. We have introduced this new and modern corporate identity with our customers in mind. Our business units no longer communicate singly with our diverse customer base, but present a coordinated and unified approach to our clients in a more comprehensive way, which demonstrates all that Lonza can offer, now and in the future.

Partner of Choice

Lonza offers the life science industry world-class contract manufacturing and a complete range of development services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. From early concept and late-stage development to commercial leadership and mature market supply, our lifecycle management experience and track record in the field of contract manufacturing is unparalleled.

Innovative Custom Manufacturing Solutions

  • Active Pharmaceutical Ingredients (APIs)
  • Advanced Intermediates & Raw Materials
  • Highly Active & Highly Potent API’s (HAPIs/HPAPIs)
  • AgroChemicals
  • Chemical Derivatives (Ketene, Diketene, HCN)
  • Peptides
  • Biocatalysis
  • Biotransformations
  • Antibody Drug Conjugates (ADCs)
  • Recombinant Novel Proteins
  • Fragmented Antibodies (Fabs)
  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Viral Vaccines and Viral Vectors
  • Plasmid DNA
  • Cell Therapy
  • Custom Media & Buffers

Practical Knowledge, Unique Solutions

As service providers, we understand the day-to-day challenges biotechnology innovators face, and we are driven to find answers. This allows us to leverage our expert technologies and our broad-based manufacturing and development experience to provide a tailored solution that meets your immediate and long-term objectives.

Advanced Technologies and Flexible Development Services

  • Light Path™ Material Supply Services
  • Epibase™ Immunogenicity Prediction Platform
  • Tripole™ Protein Engineering Platform
  • Potelligent™ CHOK1SV Cell Line
  • The GS Gene Expression System™
  • XS Microbial Expression Technologies™
  • XSpedite Microbial Services™
  • Clean Genome® E. coli
  • Cell Line/Strain Design
  • Protein Re-engineering
  • Route Selection
  • Bio/Catalyst Design
  • Analytical Development
  • Process Development & Scale-Up
  • Process Validation & Transfer
  • Purification Development
  • Technology Development

We welcome the opportunity to be challenged by your manufacturing requirements. Whether you have immediate or long-term needs, Lonza is ready to help find a custom manufacturing solution for you.

Lonza Group

Muenchensteinerstrasse 38

Basel, Switzerland

Phone U.S.: 201.316.9200

Europe: +41 61 316 81 11

Website www.lonza.com

Date Founded 1897

Number of Employees ~8,300

Previous articleAdvertorial: ATR
Next articleEmergent Wins Potentially $1.25M Anthrax Vaccine Supply Contract